Google
ALGS — ALIGOS THERAPEUTICS INC (Healthcare >> Biotechnology)
ALGS FAQ
What is ALGS's ROE?
ALIGOS THERAPEUTICS INC reports a Return on Equity (ROE) of -284.13%.
What is ALGS's dividend yield?
ALIGOS THERAPEUTICS INC offers a dividend yield of 0.00%.
What is ALGS's Deepscope Quality Score?
Deepscope rates ALGS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ALGS?
Deepscope's AI Timing Score for ALGS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ALGS belong to?
ALIGOS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.28
Price
0.12
(2.33%)
Day Change
|
|
|---|
ALGS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.28 |
| PBV / Sector |
1.00 / 4.79
GREAT
|
| Earning Per Share | -14.94 |
| PE / Sector |
N/A / 18.05
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
0.67 M
GREAT
|
| Average 1W Daily Value |
0.36 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-12 09:43:52 |
| Symbol | ALGS |
| Name | ALIGOS THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.39 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 31.93 / 9,010.81 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Corporate Drive, South San Francisco, CA, United States, 94080
Phone: 800 466 6059
Website: https://www.aligos.com
Employees: 82
Sector: Healthcare >> Biotechnology
Description: Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
